REG4 is a Potential Biomarker for Radiochemotherapy Sensitivity in Colorectal Cancer
Authors Gao L, Wu X, Zhang L, Dai Y, Zhu Z, Zhi Y, Wang K
Received 6 December 2020
Accepted for publication 3 February 2021
Published 2 March 2021 Volume 2021:14 Pages 1605—1611
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Takuya Aoki
Lei Gao,1,* Xingjun Wu,2,* Libo Zhang,3 Yang Dai,4 Zhe Zhu,3 Yunqing Zhi,4,5 Kaijing Wang3
1Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (USTC), Hefei, Anhui, 230001, People’s Republic of China; 2Department of Oncology, Jiangsu Taizhou NO. 2 People Hospital, Jiangsu, People’s Republic of China; 3Department of Hepatological Surgery, General Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, People’s Republic of China; 4Department of Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 5Department of Gynecology, Shanghai Changning Maternity and Infant Health Hospital, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Kaijing Wang
Department of Hepatological Surgery, General Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, People’s Republic of China
Email [email protected]
Department of Gynecology, Shanghai Changning Maternity and Infant Health Hospital, Shanghai, People’s Republic of China
Email [email protected]
Purpose: Colorectal cancer (CRC) is one of the most common types of malignancies, and radiochemotherapy (RCT) followed by surgery is the recommended approach for CRC treatment. However, some cases do not respond to first-line conventional chemotherapy or even progress further after treatment. Moreover, there is a risk of severe side effects, such as radiodermatitis. Therefore, identifying predictors for RCT sensitivity is an essential step toward predicting and eventually overcoming resistance.
Materials and Methods: We used integrative bioinformatics analysis and experimental validation to show that regenerating family member 4 (REG4) may be a potential biomarker for RCT sensitivity in CRC.
Results: REG4, whose expression is upregulated in some CRC tissues and downregulated in RCT-sensitive CRC cells, was identified as a potential genetic marker for RCT sensitivity in CRC. Immunohistochemistry-based tissue microarray of human CRC was used to experimentally validate REG4 data obtained from the bioinformatics analysis.
Conclusion: Collectively, these results indicate that REG4 may be a potential biomarker for RCT sensitivity in CRC.
Keywords: radiochemotherapy resistance, regenerating family member 4, immunohistochemistry microarray, colon cancer transcriptome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]